Table 2.
Decrease in NFL level in response to disease-modifying therapies.
Reference # | DMT | QR-NFL |
---|---|---|
(88) | Natalizumab | 37% |
(95) | IFN or glatiramer acetate switch to rituximab | 21% |
(90) | Natalizumab | 20% |
(89) | Fingolimod | 33% |
(85) | Natalizumab | <16 pg/mL |
(15) | Fingolimod vs IFNβ1α | 38% |
(94) | Ibudilast | ND |
ND, No difference; QR-NFL, quantitative reduction in NFL.